Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer.
Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer.
复制标题
基于血清嗜铬粒蛋白 A 的转移性去势抵抗性前列腺癌预后。
DOI：
10.1038/s41391-018-0046-9
复制
发表时间：
2018-09
影响因子：
4.8
通讯作者：
Kohli M
中科院分区：
文献类型：
--
作者：
Giridhar KV;Sanhueza C;Hillman DW;Alkhateeb H;Carlson R;Tan W;Costello BA;Quevedo F;Pagliaro L;Kohli M
确定血清嗜铬粒蛋白A（CGA）在转移性去势抵抗性前列腺癌（mCRPC）男性患者的两队列研究中的预后价值，并与基于循环肿瘤细胞（CTC）的预后进行比较。使用256例mCRPC男性患者的筛选队列和92例mCRPC男性患者的独立验证队列，对CRPC分期的血清CGA进行了基于两个队列的评估。在这两个队列中，接受质子泵抑制剂的男性和睾酮水平非去势（>50 ng/dl）的男性均被排除在外。使用时间分辨放大穴状化合物发射在均相自动免疫荧光测定中测量血清CGA。在验证队列中，还使用FDA批准的CELLIDO ®CTC测试进行CTC计数。考克斯比例风险回归模型用于血清CGA和CTC计数与总生存期的预后相关性。在筛选队列中，200名男性有资格进行分析。中位血清CGA为100.3 ng/mL（四分位数间距67-161.3），34/200高于参考范围。在Gleason评分≥ 8的男性亚组中，CGA升高与总生存期缩短相关[风险比（HR）2.19，p = 0.017]。在验证队列中，71名符合分析条件的男性的中位血清CGA为90 ng/mL（四分位数间距为55-156），71名患者中有31名CGA升高。51%的患者的Gleason评分≥8，66/71例患者的CTC计数为26/66例CTC计数≥ 5/7.5 ml血液样本（不利）。血清CGA升高（HR 1.91，p = 0.043）和不利的CTC计数（HR 2.97，p = 0.0012）均与总生存期呈不良相关，CTC ≥ 5且血清CGA升高的患者的总生存期最短（HR 3.76，p = 0.008）。在mCRPC男性患者中，血清CGA升高与OS呈负相关。血清CGA是一种预后生物标志物，可补充CTC计数。
To determine the prognostic value of serum chromogranin-A (CGA) in a two-cohort study of men with metastatic castrate resistant prostate cancer (mCRPC) and to compare with circulating tumor cells (CTCs) based prognosis. A two cohort based evaluation for serum CGA for prognostication in CRPC stage was performed using a screening cohort of 256 men with mCRPC and an independent validation cohort of 92 men with mCRPC. In both cohorts, men receiving proton pump inhibitors and those with non-castrate levels of testosterone (>50 ng/dl) were excluded. Serum CGA was measured in a homogeneous automated immunofluorescent assay using time-resolved amplified cryptate emission. In the validation cohort, CTC enumeration was also performed using the FDA cleared CELLSEARCH®CTC test. Cox proportional hazard regression models were used for prognostic association of serum CGA and CTC counts with overall survival. In the screening cohort 200 men were eligible for analysis. The median serum CGA was 100.3 ng/mL (interquartile range 67–161.3) and 34/200 were above the reference range. In the subset of men with Gleason scores ≥ 8, elevated CGA was associated with shorter overall survival [hazard ratio (HR) 2.19, p = 0.017]. In the validation cohort for 71 men eligible for analysis the median serum CGA was 90 ng/mL (interquartile range 55–156) and 31/71 patients had an elevated CGA. 51% of patients had a Gleason score ≥8 and 66/71 patients had CTCs enumerated with 26/66 with a CTC count ≥ 5 per 7.5ml blood sample (unfavorable). Both elevated serum CGA (HR 1.91, p = 0.043) and unfavorable CTC counts (HR 2.97, p = 0.0012) were adversely associated with overall survival and patients with ≥ 5 CTCs and elevated serum CGA had the shortest overall survival (HR 3.76, p = 0.008). Elevated serum CGA was negatively associated with OS in men with mCRPC. Serum CGA represents a prognostic biomarker that may complement CTC enumeration.
登录
查看更多内容
影响因子：
23.4
作者：
Hvamstad, T;Jordal, A;Fosså, SD
通讯作者：
Fosså, SD
DOI：
10.1158/1078-0432.ccr-15-0137
发表时间：
2016-03-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Beltran H;Jendrisak A;Landers M;Mosquera JM;Kossai M;Louw J;Krupa R;Graf RP;Schreiber NA;Nanus DM;Tagawa ST;Marrinucci D;Dittamore R;Scher HI
通讯作者：
Scher HI
影响因子：
4.5
作者：
Heck, Matthias M.;Thaler, Markus A.;Retz, Margitta
通讯作者：
Retz, Margitta
影响因子：
3.9
作者：
Berruti, A;Mosca, A;Dogliotti, L
通讯作者：
Dogliotti, L
影响因子：
50.5
作者：
Bonkhoff, H
通讯作者：
Bonkhoff, H